



**Sociedad Cubana
de Hepatología**



Historia natural de la cirrosis hepática por virus C.

**Resultados de estudios prospectivos e impacto del
tratamiento antiviral en la modificación de su historia natural.**



**Dr. C Eduardo Vilar
Instituto de Gastroenterología**

CLASIFICACIÓN SEGÚN ESTADO DE COMPENSACIÓN


Según clasificación clínica

- Descompensada: ascitis, hemorragia digestiva, encefalopatía, PBE, e ictero

Según estadios de Child-Pugh

- Descompensada: Child-Pugh ≥ 7


Según clasificación de D Amico (1996):



HISTORIA NATURAL DE LA CIRROSIS


COMO INTERPRETARLA?

COMO MODIFICARLA?



HISTORIA NATURAL DE LA CIRROSIS


PARÁMETROS A MEDIR



HISTORIA NATURAL DE LA CIRROSIS POR VIRUS C COMPENSADA

COMO INTERPRETARLA?


SubHazard ratio for stage 2= 4.4 (95% CI: 2.4 - 8.2), P<0.0001




Nb. at risk

Stage1	294	288	286	244	228	204	184	160	144	120	98	72	60
Stage2	108	106	104	86	78	62	50	30	28	22	14	10	8


SubHazard ratio for stage 2= 3.6 (95% CI: 1.8 - 7.5), P<0.0001





Nb. at risk


Stage1 294 294 294 254 254 150 150 122 120 68 68 48 48



No. at risk

Stage1	294	288	280	234	220	188	174	152	138	110	92	68	56
Stage2	108	104	102	82	72	48	38	20	18	10	6	4	4

SubHazard ratio for stage 2= 2.6 (95% CI: 1.6 - 4.4), P<0.0001




No. at risk

Weeks

Stage1 294 288 280 234 220 190 176 154 136 110 92 68 58


Stage2 108 104 102 82 72 56 44 24 22 14 8 6 4

SubHazard ratio for stage 2= 15.9 (95% CI: 5.9 - 42.6), P<0.0001




Stage1	294	288	286	242	228	202	182	158	144	118	98	72	58
Stage2	108	106	104	86	78	58	48	26	24	18	10	6	6

SubHazard ratio for stage 2= 2.5 (95% CI: 1.1 - 5.9), P=0.035




No. at risk		Weeks											
Stage1	294	288	284	238	224	198	178	154	142	118	98	72	60
Stage2	108	106	104	86	78	60	50	28	26	20	14	10	8



No. at risk

Stage1	294	286	284	238	226	200	180	156	144	118	98	72	60
Stage2	108	106	104	86	78	64	52	30	28	22	14	10	8

SubHazard ratio for stage 2= 1.6 (95% CI: 0.8 - 3.3), P=0.21



No. at risk


Stage1	294	288	280	236	220	188	174	152	138	110	92	68	56
Stage2	108	104	102	82	72	48	38	20	18	10	6	4	4

HISTORIA NATURAL DE LA CIRROSIS POR VIRUS C COMPENSADA

COMO MODIFICARLA?

Effect of peginterferon on major clinical outcomes in pts with HCV-related cirrhosis

A Primary Outcome




No. at Risk

Treatment group
Control group

494	479	470	457	369	358	339	321	283
499	483	474	461	382	368	356	335	285



B Clinical Outcome




No. at Risk

Cirrhosis treatment group	208	195	187	178	165	159	146	131	124
Cirrhosis control group	220	206	198	187	177	167	156	136	125
Noncirrhotic-fibrosis treatment group	309	300	295	287	281	270	259	243	234
Noncirrhotic-fibrosis control group	313	300	297	288	281	272	266	248	234

Effect of peginterferon on major clinical outcomes in pts with HCV-related cirrhosis




Extended effect of peginterferon on major clinical outcomes in HCV-related cirrhosis



Extended effect of peginterferon on major clinical outcomes in HCV-related cirrhosis


B




No. at Risk

Fibrosis Trt	308	291	283	270	247	227	175	71	18
Fibrosis Cntl	313	296	287	276	259	232	187	81	23
Cirrhosis Trt	207	195	189	172	148	128	97	50	11
Cirrhosis Cntl	220	209	199	177	152	136	108	47	12


Extended effect of peginterferon on overall mortality in HCV-related cirrhosis



Extended effect of peginterferon on overall mortality in HCV-related cirrhosis




Extended effect of peginterferon on overall mortality in HCV-related cirrhosis




Extended effect of peginterferon on overall mortality in HCV-related cirrhosis

C




HISTORIA NATURAL DE LA CIRROSIS POR VIRUS C DESCOMPENSADA


COMO ENTENDERLA?



No. at risk													
Stage 1	225	209	189	159	153	132	128	108	102	63	58	37	14
Stage 2	114	106	100	78	74	53	53	36	34	18	14	9	0
Stage 3 or 4	131	100	87	59	53	36	34	21	19	13	11	7	1




No. at risk	0	26	52	78	104	130	156	182	208	234	260	286	312
Stage 1	225	207	187	157	153	130	126	106	102	63	58	37	14
Stage 2	114	104	98	78	72	51	51	34	32	18	14	9	0
Stage 3 or 4	131	100	87	59	51	34	34	21	19	13	11	6	1



No. at risk													
Stage 1	225	205	179	149	143	120	118	102	98	59	56	35	12
Stage 2	114	99	93	73	67	43	43	26	24	10	8	5	0
Stage 3 or 4	131	82	56	30	19	13	9	3	3	3	3	1	1

Effect of peginterferon on overall mortality in decompensated HCV-related cirrhosis



	months					
Pts at risk	0	6	12	18	24	30
SVR	13	13	13	13	13	13
NonR	48	47	45	43	40	24
Ctrl	59	58	57	52	48	33




Fig. 1. Overall survival in responders, non-responders, and untreated patients.

Incidence of adverse events during peginterferon treatment

	No. of patients (%)	
	Control (<i>n</i> = 63)	PEG-IFN + RIB (<i>n</i> = 66)
Patients with events	42 (66.6)	45 (68.2)
Types of events		
Ascites	15 (23.8)	12 (18.2)
Encephalopathy	12 (19)	8 (12.1)
Bleeding	6 (9.5)	4 (6.1)
Hepatocarcinoma	2 (3.2)	2 (3)
Infective: total	9 (14.3)	19 (28.8)
Severe	4 (6.4)	11 (16.6)
Deaths: total	4 (6.3)	5 (7.6)
Related to infection	2 (3.2)	4 (6.1)


	No. of patients (%)		
	Control (<i>n</i> = 59)	No SVR (<i>n</i> = 48)	SVR (<i>n</i> = 13)
Patients with events	52 (88.1)	33 (68.7)	3 (23.1)
Types of events			
Ascites	39 (66.1)	22 (45.8)	1 (7.7)
Encephalopathy	37 (62.7)	25 (52)	2 (15.4)
Bleeding	18 (30.5)	10 (20.8)	0 (0)
Hepatocarcinoma	6 (10.1)	5 (10.4)	0 (0)
Severe infections	20 (33.9)	12 (25)	1 (7.7)
Deaths: total	19 (32.2)	10 (20.8)	0 (0)
Liver failure	18 (30.5)	9 (18.7)	0 (0)

HISTORIA NATURAL DE LA CIRROSIS POR VIRUS C COMPENSADA


CUÁL ES EL FUTURO EN EL TRATAMIENTO?

**TRIPLE TERAPIA CON INHIBIDORES
DE PROTEASA Y POLIMERASA**

Effect of viusid on major clinical outcomes in pts with decompensated HCV-related cirrhosis




Number at risk		Weeks											
CP - A - Viusid	32	(0)	32	(0)	30	(0)	29	(1)	28	(1)	26	(0)	26
CP - A - Placebo	29	(0)	29	(0)	28	(0)	28	(2)	24	(1)	23	(0)	23
CP - B/C - Viusid	18	(0)	18	(1)	16	(1)	14	(1)	12	(0)	11	(0)	10
CP - B/C - Placebo	21	(1)	20	(1)	19	(1)	18	(1)	17	(4)	11	(2)	8




Number at risk		Weeks											
CP - A - Viusid	32	(0)	32	(1)	30	(1)	28	(1)	27	(2)	24	(1)	23
CP - A - Placebo	29	(0)	29	(1)	27	(0)	27	(4)	21	(3)	20	(0)	20
CP - B/C - Viusid	18	(0)	18	(2)	15	(4)	11	(2)	9	(0)	7	(0)	7
CP - B/C - Placebo	21	(1)	20	(2)	18	(3)	15	(4)	10	(3)	6	(3)	3

Effect of viusid on major clinical outcomes in pts with HCV-related cirrhosis



Number at risk

Viusid	50	(0)	50	(0)	46	(2)	41	(2)	38	(2)	32	(1)	31
Placebo	50	(0)	49	(2)	47	(2)	43	(6)	34	(5)	26	(4)	22



Number at risk

Viusid	50	(0)	50	(1)	45	(4)	41	(0)	40	(1)	33	(0)	32
Placebo	50	(0)	48	(2)	47	(0)	44	(6)	36	(5)	28	(2)	26